Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 Antibody BMS936558

This study is currently recruiting participants.
Verified February 2013 by H. Lee Moffitt Cancer Center and Research Institute
Sponsor:
Collaborators:
Medarex
Bristol-Myers Squibb
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
NCT01176474
First received: August 5, 2010
Last updated: February 20, 2014
Last verified: February 2013

August 5, 2010
February 20, 2014
July 2010
September 2014   (final data collection date for primary outcome measure)
Time to Relapse [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
The primary efficacy analysis is time to relapse, to determine relapse at the end of each cycle (Weeks 12 and 24). Time to relapse will be summarized using descriptive statistics.
  • Time to relapse [ Designated as safety issue: No ]
  • Safety and tolerability [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01176474 on ClinicalTrials.gov Archive Site
Overall Survival (OS) [ Time Frame: 2 years, 6 months ] [ Designated as safety issue: No ]
Overall survival will be the secondary efficacy endpoint.
  • Relapse-free survival [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 Antibody BMS936558
A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 or Ipilimumab With BMS-936558 for Patients With Resected Stages IIIC/IV Melanoma

The purpose of this study is to test the side effects of an investigational vaccine with an immune booster. Investigators also wish to find out its effects on the immune system and whether it will decrease the chance that melanoma will return.

This phase I trial is studying the side effects and best dose of anti-PD-1 human monoclonal antibody MDX-1106 when given together with and vaccine therapy in treating patients with stage IIIC or stage IV melanoma that has been removed by surgery.

Blood and serum samples are collected periodically for immunology and pharmacokinetic studies.

After completion of study treatment, patients are followed up for up to 2 years.

Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Melanoma (Skin)
  • Biological: NY-ESO-1
    NY-ESO-1 peptide vaccine
    Other Names:
    • NSC 717388
    • peptide vaccine
  • Biological: BMS-936558
    BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1).
    Other Names:
    • NSC 748726
    • Anti PD-1
    • antibody
    • MDX-1106
    • Immunotherapy
    • HMA
  • Biological: gp100:280-288(288V)
    gp100:280-288(288V) peptide vaccine
    Other Names:
    • NSC 683473
    • peptide vaccine
  • Drug: Montanide
    Montanide ISA 51 vegetable grade (VG)
    Other Name: NSC 737063
Experimental: Phase I Dose Escalation
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG with Escalating Doses of Anti-PD-1 Antibody BMS-936558. Level 1: 1 mg/kg BMS-936558 + peptide vaccine. Level 2: 3 mg/kg BMS-936558 + peptide vaccine. Level 3: 10 mg/kg BMS-936558 + peptide vaccine.
Interventions:
  • Biological: NY-ESO-1
  • Biological: BMS-936558
  • Biological: gp100:280-288(288V)
  • Drug: Montanide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
62
September 2014
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologic diagnosis of resected Stages IIIC/ IV melanoma, with no evidence of disease clinically and radiologically. All melanomas regardless of primary site of disease will be allowed.
  • HLA-A*0201 positive as determined by deoxyribonucleic (DNA) allele-specific polymerase chain reaction (PCR) assay; HLA restriction is not required for cohort 4
  • Positive staining of most recently resected tumor tissue with antibodies to 1 or more of the following: human melanoma black 45 (HMB 45) for gp100, NY-ESO-1, and/or MART-1
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all adverse events have either returned to baseline or stabilized.
  • Prior treated brain or meningeal metastases must be without magnetic resonance imaging (MRI) evidence of progression for at least 8 weeks and off immunosuppressive doses of systemic steroids (> 10 mg/day prednisone or equivalent) for at least 2 weeks before study drug administration.
  • Prior systemic radiation therapy must have been completed at least 4 weeks before study drug administration. Prior focal radiotherapy completed at least 2 weeks before study drug administration. No radiopharmaceuticals (strontium, samarium) within 8 weeks before study drug administration.
  • Immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses > 10 mg/day prednisone or equivalent) must be discontinued at least 2 weeks before study drug administration.
  • Completed nitrosourea treatment at least 6 weeks before administration of any study drug.
  • Prior surgery that required general anesthesia must be completed at least 4 weeks before study drug administration. Surgery requiring local/epidural anesthesia must be completed at least 72 hours before study drug administration and participants should be recovered.
  • Screening laboratory values must meet the following criteria: white blood cells (WBCs) ≥ 2000 cells/μL, neutrophils ≥ 1500 cells/μL, platelets ≥ 100 x 10^3/μL, hemoglobin ≥ 9.0 g/dL, serum creatinine ≤ 2 mg/dL, aspartic transaminase (AST) ≤ 2.5 x upper limit of normal (ULN) without, and ≤ 5 x ULN with hepatic metastasis, alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis, bilirubin ≤ 2 x ULN (except participants with Gilbert's syndrome, who must have total bilirubin < 3.0 mg/dL).
  • Females of childbearing potential (FOCBP) must: Agree to use using a reliable form of contraception (e.g., oral contraceptives, intrauterine device, double barrier method of condom and spermicidal) for at least 28 days prior to the first dose of any study drug, during the Treatment Period (and Treatment/Follow-up if receiving study drug), and for at least 70 days after the last dose of any study drug; have a negative serum β-human chorionic gonadotropin (β-HCG) at Screening.
  • For female participants to be considered as not having childbearing potential, they must meet 1 or more of the following criteria: postmenopausal for at least 24 consecutive months; surgically sterile (ie, have had a hysterectomy or bilateral oophorectomy); females with irregular menstrual periods and/or on hormone replacement therapy must have a documented serum follicle stimulating hormone level > 35 mIU/mL.
  • Male participants must agree to the use of male contraception during the Treatment Period and for at least 180 days after the last dose of any study drug.
  • Must have read, understood, and provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained.
  • Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.

Exclusion Criteria:

  • History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).
  • Systemic hypersensitivity to Montanide ISA 51 VG or any vaccine component.
  • Prior non-melanoma malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast.
  • Any active autoimmune disease or documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for participants with vitiligo or resolved childhood asthma/atopy.
  • Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
  • Positive tests for hepatitis B virus surface antigen (HBV SAg) or hepatitis C virus ribonucleic acid (HCV RNA) indicating active or chronic infection.
  • Prior therapy with an anti-Programmed Death-1(anti-PD-1), anti-Programmed Death-Ligand 1 (anti-PD-L1), anti-programmed death-ligand-2 (anti-PD-L2), or anti-cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody(or any other antibody targeting T cell co-stimulation pathways).
  • Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids.
  • Underlying medical condition (eg, a condition associated with diarrhea) that, in the Investigator's opinion, would make the administration of either study drug or both study drugs hazardous to the participant or obscure the interpretation of toxicity determination or adverse events.
  • Pregnant or nursing.
  • Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study.
Both
16 Years and older
No
Not Provided
United States
 
NCT01176474
MCC-15651, NCI-8316
No
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
  • National Cancer Institute (NCI)
  • Medarex
  • Bristol-Myers Squibb
Principal Investigator: Jeffrey S. Weber, M.D., Ph.D. H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP